3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
71
CNS
3
Gastrointestinal
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Conditions
Thyroid Cancer, Papillary
4
Thyroid Neoplasms
3
Thyroid Carcinoma, Anaplastic
2
Thyroid cancer, follicular
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
Nivolumab
2
Bortezomib
2
vatalanib
1
tovorafenib
1
tipifarnib
1
spartalizumab
1
sargramostim
1
romidepsin
1
pentetreotide
1
pasireotide
1
milademetan
1
fludarabine phosphate
1
entrectinib
1
entinostat
1
dabrafenib
1
cobimetinib
1
avelumab
1
alectinib
1
aldesleukin
1
Vemurafenib
1
Taxes
1
Specimen Handling
1
Rose Bengal
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
PLX8394
1
Molecular Diagnostic Techniques
1
Microscopy, Electron
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Vemurafenib
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled